Presenting stage and risk group in men dying of prostate cancer.

Prostate cancer remains the 3rd leading cause of cancer-related mortality in Canadian men, and yet screening for prostate cancer continues to be controversial because the majority of men diagnosed with prostate cancer do not die of the disease. It also remains uncertain whether treatment of cases that can be treated with curative intent alters the mortality rate. There are very few studies describing the presenting stage, risk groups, and survival after diagnosis for men dying of prostate cancer in the literature. In this study, we explored these characteristics for all men who died of prostate cancer in British Columbia between 2013 and 2015. The population-based BC Cancer databases were used to identify all patients diagnosed between January 2013 and December 2015 who died of prostate cancer. Patient, tumour, and treatment characteristics were collected, and the risk grouping for each tumour was determined. The proportion of cases in each risk group at the time of diagnosis was determined. Survival time from diagnosis to death was calculated for all patients and for each risk group using the Kaplan-Meier method. A total of 1256 patients died of prostate cancer. Of patients who presented with metastatic disease, 57.2% presented with a Gleason score of 8 or more, compared with only 35.7% of patients who presented with nonmetastatic disease ( This population-based analysis demonstrates that patients with localized high-risk, regional, or metastatic disease at diagnosis constitute the overwhelming majority of patients who die of prostate cancer in British Columbia. Unless these disease states can reliably be identified at an earlier low- or intermediate-risk localized state in the future, it is unlikely that treatment of localized low- and intermediate-risk cancer will have an impact on survival. Furthermore, patients with

Informations de copyright

2020 Multimed Inc.

Déclaration de conflit d'intérêts

CONFLICT OF INTEREST DISCLOSURES We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare the following interests: SP reports honoraria from Janssen, Astellas, Bayer, Pfizer, and AstraZeneca; KNC reports grant support, consulting fees, and lecture fees from Janssen, Astellas Pharma, and Sanofi; also grant support and consulting fees from Essa Pharma, Bayer, Pfizer, Roche, and AstraZeneca; TP reports speakers’ bureau or honoraria from AbbVie, Sanofi, Servier, Ferring, and Bayer; also consulting fees from AbbVie, Tersera, and Astellas; ST reports speaking events for Bayer and clinical trials for Janssen. The remaining authors have no conflicts to disclose.